Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$2.48MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Arun Swarup Menawat
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 162
- Beta
- 0.53
- Country
- CA
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 7.08
Financials
Revenue
$2.48M+319.8%Net Income
$-9.54MEBITDA
$-9.35MFree Cash Flow
$-11.34MEPS (diluted)
$-0.26Shares Outstanding (diluted)
36.35M+820.7%Operating Expenses
$13.01MCash & Debt
$38.27MRevenue by Segment (annual)
$16.10MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $16.38M | $-43.32M | $-1.43 |
| 2024 | $10.17M | $-26.48M | $-1.07 |
| 2023 | $7.20M | $-28.57M | $-1.35 |
| 2022 | $6.68M | $-28.67M | $-1.38 |
| 2021 | $6.87M | $-30.70M | $-1.50 |
| 2020 | $7.30M | $-21.62M | $-1.25 |
| 2019 | $4.17M | $-15.22M | $-1.39 |
| 2018 | $1.91M | $-15.24M | $-1.52 |
| 2017 | $4.90M | $-19.10M | $-2.44 |
| 2016 | $0.00 | $-12.15M | $-3.93 |
| 2015 | $0.00 | $-11.80M | $-6.91 |
| 2014 | $0.00 | $-8.20M | $-37.86 |
| 2013 | $0.00 | $-14.22M | $-65.62 |
| 2012 | $0.00 | $-9.14M | $-42.17 |
Valuation
PROFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·6h ago·Positive
Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg analyst consensus by approximately 45% to 47% Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg analyst consensus by approximately 45% to 47%
View source ↗ - Newsglobenewswire.com·34d ago·Positive
Profound Medical to Participate in Lake Street's 10th Annual Best Ideas Growth Conference TORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, announced today that management will participate in the Lake Street Capital Markets “BIG10” Conference on September 10, 2026 in New York City.
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
Profound Medical Announces Management Change TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced the promotion of Matthew Sobczyk from Corporate Controller to Interim Chief Financial Officer, effective immediately. Mr. Sobczyk, who first joined Profound in 2020, succeeds Rashed Dewan, who has stepp…
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.23 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.26 vs $-0.22miss
- Thu, May 7$-0.19 vs $-0.24beat
- Thu, Mar 5$-0.27 vs $-0.27beat
- Thu, Nov 13$-0.26 vs $-0.38beat
- Thu, Aug 14$-0.52 vs $-0.43miss
- Thu, May 8$-0.36 vs $-0.29miss
Estimates and results for PROF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PROF officers and directors.
- Bought
- $109k
- Sold
- $6k
7 trades
1 trade
- Menawat Arun Swarupbought
- Menawat Arun Swarupbought
- Hofer Michaelsold
- Hofer Michaelbought
- Tejada Fredbought
- Blanchet Justinbought
- Schweitzer John H.bought
- Hofer Michaelbought
4 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Tom Malinowskihouse · NJ07 · disclosed Mar 5, 2021 (441d later)Buy$1,001 - $15,000
- Tom Malinowskihouse · NJ07 · disclosed Mar 5, 2021 (227d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.